Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation
Completed
Conditions studied: Lymphoma
In brief
The purpose of this study is to determine if higher absolute lymphocyte count in the infused stem cell autograft (A-ALC) will lead to an improved antibody response to post-transplant immunization with Pneumococcal Conjugate Vaccine and permit effective immunization at 6 months post-transplant in lymphoma patients receiving Autologous Peripheral Blood Stem Cell Transplantation.
Key facts
- Study ID
- NCT00889278
- Run by
- Dartmouth-Hitchcock Medical Center
- People needed
- 30
- Starts
- 2008-02-01
- Expected to finish
- 2016-01-05
- Last updated by the study team
- 2018-05-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 18 years of age or older
- Lymphoma or lymphoproliferative disease diagnosis
- Scheduled APBSCT
- Able to give informed consent and comply with the procedures of the study
- Enrollment in other interventional trials are allowed at the discretion of the investigators
You may not qualify if…
- Contraindication to Prevnar®
- Has received immune globulin within 5 months prior to being enrolled on the study or plans to receive immune globulin prior to the day +270 (+/-30) visit
- Currently participating in, or scheduled to participate in any clinical trial using investigational immune modulators (e.g. IL-2) at any time prior to the completion of follow-up in this study.
- Any other underlying medical condition that, in the opinion of the investigator, may interfere with the evaluation of study objectives
- Day +180(+/- 30days) Eligibility:
- Has received immune globulin within the past 5 months prior to the receipt of the vaccine or plans to receive immune globulin prior to the day +270(+/- 30) visit
- Is pregnant (as determined by urine or serum B-HCG test)
- Participant has a contraindication to Prevnar®
- A recent (<72 hours) febrile illness (axillary temperature >99.5°F [>37.5°C], oral temperature >100.3oF [>37.9oC], or rectal temperature >101.3°F[>38.5°C]) prior to the study vaccination
Where it is running
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.